lhrh, n-ac-(4-cl-phe)(1)-(4-clphe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)- profile

Org 30850: gonadorelin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	25078151
MeSH ID	M0185330

Synonyms (11)

Synonym
1-n-ac-(4-cl-phe)-2-(4-cl-phe)-3-(3-benzo(b)thi-ala)-6-lys-10-alanh2-lhrh
lhrh, n-ac-(4-cl-phe)(1)-(4-clphe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)-
136208-71-4
d-alaninamide, n-acetyl-4-chloro-d-phenylalanyl-4-chloro-d-phenylalanyl-3-benzo(b)thien-3-yl-d-alanyl-l-seryl-l-tyrosyl-d-lysyl-l-leucyl-l-arginyl-l-prolyl-
gnrh, n-ac-4-cl-phe(1)-(4-cl-phe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)-
org 30850
org 30850 ant
lhrh, (n-acetyl-4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-(3-benzo(b)thien-3-ylalanyl)(3)-lysyl(6)-alaninamide(10)-
DTXSID90159733
(s)-1-(((r)-2-((r)-2-((r)-2-acetamido-3-(4-chlorophenyl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(benzo[b]thiophen-3-yl)propanoyl)-l-seryl-l-tyrosyl-d-lysyl-l-leucyl-l-arginyl)-n-((r)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide
AKOS040747236

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.66 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.45 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies
lhrh, lys(6)- [no description available]	1.99	1
lhrh, n-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)- LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-: gonadorelin antagonist	1.98	1
metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.	1.99	1

Condition	Relationship Strength	Studies
Hepatocellular Carcinoma [description not available]	1.99	1
Cancer of Liver [description not available]	1.99	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	1.99	1
Liver Neoplasms Tumors or cancer of the LIVER.	1.99	1
Anasarca [description not available]	1.98	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	1.98	1

lhrh, n-ac-(4-cl-phe)(1)-(4-clphe)(2)-(3-benzo(b)thi-ala)(3)-lys(6)-alanh2(10)-

Description